FDA Approves New SGLT-2 Inhibitor Brenzavvy

The US Food and Drug Administration has approved a new medication for Type 2 diabetes called Brenzavvy. This belongs to a class of drugs known as SGLT-2 inhibitors, which work by helping the body remove excess glucose (sugar) through the urine.

Brenzavvy was approved based on results from 23 clinical trials, which showed that the medication effectively lowered blood sugar levels and improved overall diabetes control. The most common side effect of Brenzavvy was yeast infections.

Brenzavvy, which can be used alone or in combination with other diabetes medications, is not approved for people with Type 1 diabetes.

Brenzavvy is now the fifth SGLT-2 inhibitor approved in the US, along with Invokana (canagliflozin), Farxiga (dapagliflozin), Jardiance (empagliflozin), and Steglatro (ertugliflozin).

To read more CLICK HERE.


Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags